Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 10/20 | 0.47 |
| ▸ | CA1 | P00915 | 9/20 | 0.47 |
| ▸ | CA12 | O43570 | 6/20 | 0.47 |
| ▸ | CA9 | Q16790 | 5/20 | 0.47 |
| ▸ | CA7 | P43166 | 5/20 | 0.47 |
| ▸ | CA5A | P35218 | 3/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | HPN | P05981 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| P-Toluenesulfonamide SCHEMBL1829285 | 0.80 | TDP1 (0.55) | ALDH1A1CA2CA1CA12CA9 | |
| SCHEMBL19469366 | 0.80 | CNR2 (0.49) | ALDH1A1TSHR | |
| P-Toluenesulfonamide SCHEMBL8964918 | 0.79 | TDP1 (0.60) | ALDH1A1CA2CA1CA12CA9 | |
| P-Toluenesulfonamide SCHEMBL28101678 | 0.79 | CA2 (0.73) | ALDH1A1CA2CA1CA12CA9 | |
| SCHEMBL7599913 | 0.75 | ALDH1A1 (0.57) | ALDH1A1CA2CA12CA9CA7 | |
| Phenylalanine SCHEMBL18191186 | 0.74 | SLC7A5 (0.63) | CA2CA1CA12CA9CA7 | |
| Dl-Phenylalanine SCHEMBL18191199 | 0.74 | SLC7A5 (0.63) | CA2CA1CA12CA9CA7 | |
| P-Toluenesulfonamide SCHEMBL28234027 | 0.74 | CA1 (0.66) | CA2CA1CA12CA9CA7 | |
| P-Toluenesulfonamide SCHEMBL5691991 | 0.73 | CA2 (0.82) | CA2CA1CA12CA9CA7 | |
| SCHEMBL11827938 | 0.72 | FFAR1 (0.45) | ALDH1A1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008112707-A1 | IMMUNOACTIVE COMPOSITIONS FOR IMPROVED ORAL DELIVERY OF VACCINES AND THERAPEUTIC AGENTS | PEROS SYSTEMS TECHNOLOGIES, INC. (CA) | 2008-09-18 | — | — | WO | disclosed |
| US-20080226682-A1 | Immunoactive Compositions for Improved Oral Delivery of Vaccines and Therapeutic Agents | PEROS SYSTEMS TECHNOLOGIES, INC. | 2008-09-18 | — | — | US | disclosed |
| US-7314916-B2 | Methods and materials for characterizing and modulating interaction between heregulin and HER3 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-01-01 | — | — | US | disclosed |
| US-7125680-B2 | Methods and materials for characterizing and modulating interaction between heregulin and HER3 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-10-24 | — | — | US | disclosed |
| US-20060177907-A1 | Methods and materials for characterizing and modulating interaction between heregulin and HER3 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-08-10 | — | — | US | disclosed |
| US-20030143568-A1 | Methods and materials for characterizing and modulating interaction between heregulin and HER3 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-31 | — | — | US | disclosed |
| WO-2003011897-A1 | MODULATION OF HEREGULIN AND HER3 INTERACTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-02-13 | — | — | WO | disclosed |
| US-6156731-A | Polypeptide composition for oral administration | G. D. SEARLE & CO. (US) | 2000-12-05 | — | — | US | disclosed |
| EP-0839047-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PROTEIN | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT CO. LTD. (IL) | 1998-05-06 | — | — | EP | disclosed |
| WO-1997003688-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PROTEIN | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT COMPANY LTD. (IL) | 1997-02-06 | — | — | WO | disclosed |
| EP-0202975-B1 | SOLUBLE INTERLEUKIN-2 RECEPTOR AS AN INDICATOR OF MALIGNANCY AND A METHOD OF ASSAYING THE SAME | US COMMERCE (US) | 1993-06-30 | — | — | EP | disclosed |
| EP-0526952-A2 | Soluble interleukin-2 receptor as a disease indicator and a method of assaying the same | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1993-02-10 | — | — | EP | disclosed |
| EP-0127535-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING INSULIN | HADASSAH MEDICAL ORGANIZATION (IL) | 1990-01-03 | — | — | EP | disclosed |
| US-4707443-A | Soluble interleukin-2 receptor as a disease indicator and a method of assaying the same | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1987-11-17 | — | — | US | disclosed |
| EP-0202975-A2 | Soluble interleukin-2 receptor as an indicator of malignancy and a method of assaying the same | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1986-11-26 | — | — | EP | disclosed |
| US-4579730-A | ORAL ADMINISTRATION; INSULIN BILE ACID OR SALT AND PROTEASE INHIBITOR | HADASSAH MEDICAL ORGANIZATION (IL) | 1986-04-01 | — | — | US | disclosed |
| EP-0127535-A2 | Pharmaceutical compositions containing insulin | HADASSAH MEDICAL ORGANIZATION (IL) | 1984-12-05 | — | — | EP | disclosed |